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The triglyceride and glucose lowering potential of the leaf extracts of Pterocarpus santalinoides was 
investigated in dexamethasone induced hyperlipidemia and insulin resistance in rats. Acute toxicity 
test was performed according to standard methods. An oral glucose tolerance test was carried out in 
the presence of the extracts in normal rats. Then, graded doses of aqueous and methanol extracts of P. 
santalinoides (AEPS and MEPS) were administered orally to rats in four groups, respectively, after a 12 
h fast followed by subcutaneous administration of dexamethasone (10 mg/kg body wt). Rats in a fifth 
group received saline (5 ml/kg p.o) followed by dexamethasone (10 mg/kg body wt s.c) and served as 
positive control while a sixth group served as normal control. The period of extract and dexamethasone 
administration was 10 days. Acute toxicity test showed that the extract had an oral LD50 > 5000 mg/kg in 
rats. Graded doses of  aqueous and methanol extracts of P. santalinoides to glucose loaded normal rats 
resulted in significant lowering of blood glucose concentration which started at 90 min post-glucose 
load when compared with the 60 mine (peak) sample (p < 0.001) and also when compared with the 
negative control value at 90 min (p < 0.001). Administration of dexamethasone to fasted rats for 10 days 
resulted in hyperlipidemia and insulin resistance  evidenced by the significant increase in mean 
glucose level (194.50 ± 9.87 mg/dl) and triglyceride level (268.75 ± 21.54 mg/dl) in the positive control 
when compared with the normal control with mean glucose and triglyceride concentrations of 64.00 ± 
3.44 mg/dl and 100.00 ± 15.54 mg, respectively (p < 0.01; p < 0.001). Graded doses of the AEPS and 
MEPS significantly antagonized dexamethasone induced hyperlipidemia and insulin resistance in rats 
when compared with the positive control (p < 0.001) and the normal control, respectively (p < 0.05). The 
antagonistic potency of AEPS was dose dependent while that of the MEPS was not. The leaf extracts of 
P. santalinoides possess triglyceride and glucose lowering properties in dexamethasone induced 
hyperlipidemia and insulin resistance and could be of therapeutic value in the management of 
metabolic syndrome. 
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Dexamethasone is a potent synthetic member of the 
glucocorticoid class of steroid hormones. It acts as an 
anti-inflammatory and immunosuppressant. Diabetes 
mellitus is a chronic metabolic disorder and a growing 
medical problem which the etiology and pathogenesis is 
not fully understood (Harris, 1995). In type 2 diabetes, 
insulin resistance leads to an inability of insulin to control 
the activity of gluconeogenic enzymes and results in 
significant elevation of hepatic glucose production (Barthel 
and Schmoll, 2003). This is accompanied by abnormalities in 
lipid and protein metabolism, and together these metabolic 
perturbations can lead to serious complications  including 




nephropathy, retinopathy, neuropathy and coronary artery 
disease (Cooper, 1998; Ferris et al., 1999; Backonja et al., 
1998). Excessive glucocorticoid (GC) action is known to 
cause a spectrum of clinical features such as obesity, 
insulin resistance and glucose intolerance as exemplified 
in Cushing’s syndrome (Andrew and Walker, 1999). GCs 
promote breakdown of protein and fat from storage, 
which causes an increased supply of free fatty acids and 
branched amino acids to the liver (Zimmerman et al., 
1989).  
Pterocarpus santaniloides (Fabaceae- Papilinoideae) is 
a plant commonly referred to as Red Sandal wood in 
English, Gunduru gyadar Kurmi in Hausa, Uturukpa in 
Igbo and Gbenghe in Yoruba. The leaves are claimed in 
folk medicine to be effective oral hypoglycaemic agents 
and its stem bark is used for the treatment of stomach 
ache. Phytochemical analyses of the leaves of the plant 
show the presence of saponins, flavonoids, phenols, 
triterpenoids, and tannins (Nworu et al, 2009). Most 
commonly employed oral hypoglycaemic agents are 
sulphonylureas and biguanides. These drugs, however, 
have disadvantages such as primary and secondary 
failure of efficacy as well as the potential for the induction 
of severe hypoglycaemia (Dow et al., 1991). There is 
need, therefore, for new candidate molecules that may 
effectively reduce insulin resistance or potentiate insulin 
action in genetically diabetic or obese individuals. New 
drugs that reverse insulin resistance without stimulating 
insulin release from β- cells also fulfil a major medical 
need in the treatment of non-insulin –dependent diabetes 
mellitus (NIDDM). The search for drugs with potential to 
reduce long term diabetic complications of NIDDM is, 
therefore, of current interest. Numerous medicinal plants 
have been used to treat diabetes mellitus and other forms 
of glucose intolerance or insulin resistance (Bajaj and 
Srinivasan, 1999; Mandal et al., 2000; Vikrant et al., 
2000; Bhattacharya, 1995). The aim of this study is to 
evaluate the glucose and triglyceride lowering properties 
of the leaf extracts of P. santalinoides in dexamethasone-
induced hyperlipidaemia and insulin resistance. 
 
 




Male albino Wistar rats (100 -130 g) were procured from the Animal 
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Campus. These rats were housed in clean guazed cages at the 
Animal House of the College of Medicine, University of Nigeria, 
Enugu Campus under standard condition of temperature (28 ± 2°C) 
and with a 12:12 h light/dark periodicity. The period of acclima-
tization was (2) weeks. Animals were handled in this study according to 
international and institutional guidelines on experiments involving 





Absolute methanol (May and Baker, Nigeria Plc) NaCl (May and 
Baker, Nigeria Plc). Dexamethasone sodium phosphate (Troge, 
Germany) triglyceride and glucose estimation kits (Quimica Clinica 
applicada laboratories, Spain). Other reagents were of the analy-
tical reagent grade.  
 
 
Plant collection and taxonomy  
 
The leaves of P. santaniloides were collected from a residential 
quarters at the University of Nigeria, Enugu Campus between the 
month of January and February, 2009. The plant sample was 
authenticated by a taxonomist at the Department of Botany, 
University of Nigeria, Nsukka. A voucher specimen was deposited 
at the Department of Medical Laboratory Sciences, College of 
Medicine, University of Nigeria, Enugu Campus (MLSH/63 d). The 
leaves were dried under the shade and powdered using an electric 
blender or Mill grater (MS 223, Taiwan).  
 
 
Plant extraction  
 
Aqueous extraction  
 
Powdered plant leaves (1000 g) were macerated in 500 ml of 
distilled water and agitated intermittently for 48 h. After 48 h the 
extract obtained was strained through muslin and then through a 
Whatman No.1 filter paper. The aqueous extract of P. santalinoides 





Powdered plant leaves (1000 g) were macerated in 3.5 litres of 
80% methanol for 48 h. After 48 h, the extract was filtered through a 
Whatman No.1 filter paper. The filtrate was evaporated to dryness 
on a rotary evaporator (model 349/2 Corning, England) and the 
residue stored in the refrigerator (4 ± 2°C) until required. The yield 
of the methanolic extract of P santalinoides (MEPS) was 10.2%. 
The methanolic extract (10 g)  was dissolved in physiological saline 
and made up to 100 ml with the same solvent. Appropriate dilutions 
were made from this for the study.  
 
 
Acute toxicity tests (LD50) 
 




Glucose tolerance tests 
 
Rats were divided into six groups (A - E) of 5 rats each. Blood 
samples were collected from rats in all the groups following an 
overnight fast (Fasting or 0 h sample). Groups A - E received 200 
mg/kg aqueous extract of P. santalinoides (AEPS), 400 mg/kg 
AEPS, 200 mg/kg methanol extract (MEPS) and 400 mg/kg  MEPS,  




Table 1. The effect of the extracts of P santalinoides on glucose tolerance of normal glucose fed rats. 
 
Treatment group FBS (0 h) Gluc at 30 min Gluc at 60 min Gluc at 90 min Gluc at 120 min Gluc at 150 min 
A(200 mg/kg AEPO 97.50 ± 3.86 163.85 ± 4.50 195.35 ± 3.94 150.47 ± 4.56** 110.83 ± 3.87** 80.60 ± 4.38** 
B(400 mg/kg AEPO) 85.00 ± 4.32 155.60 ± 4.45 180.50 ± 3.81 135.45 ± 5.70** 96.33 ± 5.21** 69.50 ± 4.56** 
C(200 mg/kg MEPO) 84.62 ± 2.45 177.67 ± 5.92 200.00 ± 5.25 156.50 ± 6.20** 114.83 ± 4.22** 90.37 ± 3.75** 
D(400 mg/kg MEPO) 70.15 ± 6.38 160.83 ± 3.36 220.33 ± 5.06 137.24 ± 5.12** 99.60 ± 4.57** 68.83 ± 3.40** 
E(Saline Negative control) 91.67 ± 3.53 166.83 ± 4.38 216.17 ± 3.90 248.00 ± 9.07* 220.45 ± 5.91 146.67 ± 4.81** 
 
*p < 0.05; **p < 0.001 with respect to the 60 min (peak) glucose level; n = 5. Glucose concentrations are in mg/dl and expressed as mean ± SEM. FBS = fasting blood 




respectively. Group E received saline (5 ml/kg) and served 
as vehicle control. All administration was by oral route 
(p.o). The rats in all the groups were loaded with 60% 
glucose (3 gm/kg, p.o) (Babu et al., 2002), thirty (30) min 
after extract administration. Blood samples were collected 
from the tail at 30, 60, 120, and 150 min after glucose 
loading. Blood glucose levels were measured immediately 
with a glucometer (Contour
®
 Bayer Health Care Systems 
LLC, Mishawaka IN, USA). 
 
 
Dexamethasone induced insulin resistance and 
hyperlipidemia  
 
Twenty-four (24) male albino wistar rats (100 - 130 g) were 
divided into six (6) groups (A - F) of 4 rats per group. Rats 
in group A - E received saline (vehicle, 5 ml/kg body 
weight), 200 mg/kg of AEPS, 400 mg/kg of AEPS, 200 
mg/kg MEPS, and 400 mg/kg MEPS, respectively. 
Additionally, dexamethasone (10 mg/kg sub-cutaneously) 
was given to all the animals in groups A - E. Group A serv-
ed as the positive control group while group F received 
only vehicle (Saline, 5 mg/kg) and served as normal or 
negative control group. All the animals received their 
respective treatments daily for a period of 10 days. Rats in 
group A - E were fasted overnight before dexamethasone 
treatment as described by Manhendran and Devi (2001). 
On the 11th day, blood was collected from the animals by 
retro-orbital puncture under ether anesthesia and serum 
was separated for the estimation of glucose and trigly-
ceride.  
Blood glucose determination  
 
Fasting blood sugar was measured with the glucose 





Triglyceride was estimated by enzymatic method as 
described by Fossati and Precipe, (1982).   
 
 
Statistical analysis  
 
The results were expressed as mean ± standard error of 
mean (SEM). Differences between means was determined 
by student’s t-test followed by Scheffes post-hoc multiple 





Acute toxicity test showed that the extract had an 
oral LD50 > 5000 mg/kg in rats. Oral administration 
of a glucose load in fasted rats resulted in an 
increase in blood glucose level which peaked at 1 
h post glucose load (Table 1). Administration of 
graded doses of aqueous and methanol extracts 
of P. santalinoides (AEPS and MEPS) resulted in 
significant lowering of blood glucose concentration 
which started at 90 min post-glucose load when 
compared with the 60 min (peak) sample (p < 
0.001) and also when compared with the negative 
control value at 90 min (p < 0.001). The glucose 
lowering effect of both extracts was consistent 
and normoglycemic values were obtained at 120 
min when compared with the negative control.  
In Table 2, the mean glucose and triglyceride 
levels of treated animals were compared with 
those of the untreated (normal) control. Results 
showed that administration of dexamethasone (10 
mg/kg) resulted in insulin resistance and hyper-
lipidemia as evidenced by the significant in 
increase in mean glucose (194.50 ± 9.87 mg/dl) of 
the positive control (Dexamethasone + saline) 
when compared with the baseline (negative 
control) that had mean glucose and triglyceride 
concentrations of 64.00 ± 3.44 mg/dl as 100.00 ± 
15.54 mg/dl, respectively (p < 0.01, p < 0.001). 
Group C which received 400 mg/kg of the 
aqueous leaf extract of P.  santalinoides (AEPS) 
prior to dexamethatone administration had mean 
glucose (GLU) and triglyceride (TG) levels of 
76.75 ± 6.28 mg/dl and 141.25 ± 21.44 mg/dl 
which   were   not  significantly  different  from  the 
baseline values (p > 0.05), indicating an antagonism  




Table 2. Comparison of mean glucose and triglyceride concentration (mean ± SEM) of treatment groups with normal and positive 
controls. 
   
Group Dose (mg/kg) Glucose (mg/dl) Triglyceride (mg/dl) 
A(Positive control)  5 ml/kg saline+ Dexamethazone  194.50 ± 9.87
a
 268.75 ± 21.54
b
 
B (AEPS)  200 mg/kg AEPS+ Dexamethazone  108.75 ± 26.21
d
 167.50 ± 17.38
c,d
 
C (AEPS)  400 mg/kg AE + Dexamethasone  76.75 ± 6.25
e
 141.25 ± 21.44
f
 
D (MEPS)  200 mg/kg MEPS +Dexamethasone  72.25 ± 10.99
e
 116.25 ± 19.29
f
 
E (MEPS)  400 mg/kg ME + Dexamethasone  138.00 ± 15.25
c,d
 238.75 ± 27.94
b
 
F Normal control 5 ml/kg saline  64.00 ± 3.44 100.00 ± 15.54 
 
a = p < 0.001 with respect to normal control (N.C); b = p < 0.01 with respect to N.C; c = p < 0.05 with respect to N.C; d = p < 0.05 with 




to the glucose and triglyceride elevating property of 
dexamethasone. Group B rats received 200 mg/kg AEPS 
prior to dexamethasone injection and their mean glucose 
level was not significantly different from that of the 
baseline group (p > 0.05). However, the mean triglyceride 
concentrations of group B rats (167.50 ± 17.38 mg/dl) 
were signi-ficantly higher than that of the baseline group 
(100.00 ± 15.54 mg/dl) (p < 0.05). Administration of the 
methanol leaf extract of P. santalinoides (MEPS) at a 
dose of 200 mg/kg prior to dexamethasone injection 
resulted in a non-significant mean difference between the 
mean glucose and triglyceride levels of this group and the 
baseline group (p > 0.05). However, 400 mg/kg MEPS, 
had mean glucose (138.00 ± 15.25 mg/dl) and triglyceride 
(238.75 ± 27.94 mg/dl) concentrations that were 
significantly higher than those of the baseline group (p < 
0.01, p < 0.001).  
In Table 2, the mean glucose and triglyceride concen-
tration of extract treated groups was compared with the 
positive control (Dexamethasone control) group. Results 
indicate that cumulative doses (200 and 400 mg/kg) of 
the AEPS and 200 mg/kg of MEPS significantly reduced 
mean glucose and triglyceride levels after dexamet-
hasone injection when compared with the positive control 
(p < 0.001). The 400 mg/kg dose of AEPS lowered 
glucose significantly after dexamethasone injection (p < 
0.05). However, there was non-significant mean diffe-
rence in the triglyceride value. Results from this work 
indicated that the AEPS had a dose independent 
reduction in mean glucose and triglyceride levels. The 
lower dose (200 mg/kg) of MEPS had significant glucose 
and triglyceride lowering property in the setting of Dexa-
methasone induced insulin resistance and hyperlipidemia 





Insulin resistance in humans has been shown in condi-
tions like obesity, non-insulin dependent diabetes mellitus 
(NIDDM), and dyslipidemia. Thus, interventions to decrease 
insulin resistance may postpone the development of 
NIDDM and its complications. Treatment with natural herbs 
is likely to be fraught with lesser side effects compared to 
the presently used synthetic oral antidiabetic agents. 
Many medicinal plants have been reported to posses 
significant anti-diabetic effect in both type 1 and II 
diabetes mellitus as well as improved glucose tolerance 
(Bajaj and Srinivasan, 1999; Mandal et al., 2000; Vikrant 
et al., 2000; Bhattachanya, 1995). Dexamethasone is a 
potent synthetic member of the glucoscorticoid class of 
steroid hormones. Dexametha-sone administration leads 
to insulin resistance, hyperglycemia, and dyslipidemia in 
human and experi-mental animals (Amin et al, 1999; 
Bruder et al., 2004). Insulin resistance and hyperin-
sulinemia are often asso-ciated with a group of risk 
factors such as obesity, dyslipidemia, hypertension and 
impaired glucose tolerance. This cluster of metabolic 
abnormalities, first defined as syndrome X by Raven 
(1988) and supported by additional evidence (Raven, 
1991: Defronzo and Ferrannini, 1991), is now often referred 
to as metabolic syndrome and has been recognized as 
potent risk factors for coronary heart disease.                                                 
In the present study, dexamethasone administration for 
10 days in rats resulted in increased triglyceride and 
glucose levels similar to previous studies (Shalam et al., 
2006; Dai et al., 1995). The low dose (200 mg/kg) of 
MEPS and the high dose (400 mg/kg) of AEPS were very 
potent in antagonizing dexamethasone induced hypergly-
caemia and hypertriglyceridemia. Phytochemical analyses 
of the leaves of the plant show the presence of saponins, 
steroids, flavonoids, phenols, triterpenoids, and tannins 
(Nworu et al., 2009). It is likely that the glucose lowering 
property could be due to the combined effect of these 
bioactive constituents. For instance, saponins isolated 
from the leaves of Acanthopanax senticosus decreased 
experimental hyperglycemia induced by injection of 
adrenaline, glucose and alloxan (Sui et al., 1994). Flavo-
noids, saponins, alkaloids and the triterpenoids have 
been reported by several workers to possess glucose 
lowering property in diabetic animals (Nojima et al., 1998, 
Yoshikawa et al., 1998; Kamel et al., 1991). Furthermore, 
three phenolic constituents (marsupin, pterosupin, and 
pterostilbene) of a related plant (Pterocarpus marsupium) 
significantly lowered the glycemia of diabetic rats in a 





(Metformin) (Manickam et al., 1997).  
Moreover, glucocorticoid action is mediated by the 
glucocorticorticoid receptor (GR), a nuclear receptor that 
regulates physiological events through activation or 
repression of target genes involved in inflammation, 
gluconeogenesis and adipocyte differentiation (Bamberger 
et al., 1996; Schacke and Rehwinkel, 2004). It is 
therefore, probable that the extracts of P. santalinoides 
may contain substances that compete with gluco-
corticoids for the glucocorticoid receptor (competitive 
antagonism) or they may contain substances that 
stimulate the production of repressor elements that inhibit 
the transcription. That is, they may bind to negative 
glucocorticoid response elements that mediate the 
repression of gene transcription. In the liver, gluco-
corticoids increase the activities of enzymes involved in 
fatty acid synthesis and promote the secretion of 
lipoproteins (Wang et al., 1995). The hepatic lipogenic 
effect of glucocorticoids results in accumulation of 
triglycerides in the liver. This reduces insulin sensitivity in 
the liver (Samuel et al., 2004). The extract of P. 
santalinoides could also act by inhibiting the expression 
of phosphoenolpyruvate carboxykinase and glucose-6-
phosphatase.  
Furthermore, glucocorticoids antagonize insulin-
stimulated translocation of glucose transporters (e.g. 
Glut-4) from intracellular compartments to the plasma 
membrane (Carter-su and Okamoto, 1987; Horner et al., 
1987; Oda et al., 1995). This results in insulin resistance. 
The extracts could act by reversing the glucocorticoid 
mediated translocation of the glucose transporters from 
the plasma membrane to the intracellular compartment. 
The leaf extracts of P. santalinoides, therefore, appeared 
to have improved insulin resistance through enhanced 
insulin sensitivity in peripheral tissues, as was evident 
from the decreased glucose levels. However, the exact 
mechanism of action of these extracts were not estab-
lished in this study. Drugs ameliorating hyperinsulinemia 
are likely to have greater therapeutic potential as they 
may also exert beneficial effects on the clinical course of 
NIDDM, hypertension and coronary heart disease. In 
conclusion, oral administration of the leaf extracts of P. 
santalinoides reduced glucose and triglyceride concen-
trations in dexamethasone treated rats. If these results 
are extrapolated to humans, then P. santalinoides might 
prove useful in the treatment of NIDDM and/or prevention 
of insulin resistance in non-diabetic states such as 
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